The Library
Comparison of an oral factor Xa inhibitor with low molecular weight heparin in cancer patients with venous thromboembolism : results of a randomized trial (SELECT-D)
Tools
Tools
Tools
SELECT-D Collaborative Group (Including: Young, Annie M., Marshall, Andrea, Thirlwall, Jenny, Chapman, Oliver, Lokare, Anand, Hill, Catherine, Hale, Danielle, Dunn, Janet A., Lyman, Gary H., Hutchinson, Charles, MacCallum, Peter, Kakkar, Ajay, Hobbs, F. D. Richard, Petrou, Stavros, Dale, Jeremy, Poole, Christopher J., Maraveyas, Anthony and Levine, Mark). (2018) Comparison of an oral factor Xa inhibitor with low molecular weight heparin in cancer patients with venous thromboembolism : results of a randomized trial (SELECT-D). Journal of Clinical Oncology, 36 (20). pp. 2017-2023. doi:10.1200/JCO.2018.78.8034
![[img]](http://wrap.warwick.ac.uk/style/images/fileicons/application_pdf.png) |
PDF
WRAP-SELECT-D-comparison-oral-factor-Xa-inbibitor-low-cancer-venous-randomized-Petrou-2018.pdf - Published Version Embargoed item. Restricted access to Repository staff only until 10 December 2018. Contact author directly, specifying your specific needs. - Requires a PDF viewer. Download (1924Kb) |
|
PDF
WRAP-comparison-oral-factor-Xa-inhibitor-low-molecular-weight-Petrou-2018.pdf - Accepted Version Embargoed item. Restricted access to Repository staff only - Requires a PDF viewer. Download (498Kb) |
Official URL: http://doi.org/10.1200/JCO.2018.78.8034
Abstract
Purpose:
Venous thromboembolism (VTE) is common in cancer patients. Long-term daily subcutaneous low molecular weight heparin has been standard treatment for such patients. The purpose of this study was to assess if an oral Factor Xa inhibitor, rivaroxaban, would offer an alternative treatment for VTE in cancer patients. Patient and
Methods:
In this UK multicentre, randomised, open-label, pilot trial, patients with active cancer who had symptomatic pulmonary embolism (PE), incidental PE or symptomatic lower extremity proximal deep vein thrombosis (DVT) were recruited. Allocation was to dalteparin (200 IU/kg daily, month 1, then 150 IU/kg, months 2-6) or rivaroxaban (15 mg twice daily for three weeks, then 20 mg once daily) for six months. The primary outcome was VTE recurrence over six months. Safety was assessed by major bleeding and clinically relevant non-major bleeding (CRNMB). A sample size of 400 patients would provide estimates of VTE recurrence to within +/ 4.5% assuming a VTE recurrence rate at six months of 10%.
Results:
Two hundred and three patients were randomised to each group; 58% of whom had metastases. Twenty-six patients experienced recurrent VTE (18 dalteparin, 8 rivaroxaban). The six month cumulative VTE recurrence rate with dalteparin was 11% (95% CI 7-16%) and 4% (95% CI 2-9%) with rivaroxaban, hazard ratio (HR) 0.43, (95% CI 0.19-0.99). The six month cumulative rate of major bleeding was 4% (95% CI 2-8%) for dalteparin and 6% (95% CI 3-11%) for rivaroxaban, HR 1.83, (95% CI 0.68-4.96). Corresponding rates of CRNMB were 4% (95% CI 2-9%) and 13% (95% CI 9-19%) respectively, HR 3.76, (95% CI 1.63-8.69).
Conclusion:
Rivaroxaban was associated with relatively low VTE recurrence but higher CRNMB compared to dalteparin.
| Item Type: | Journal Article | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Subjects: | R Medicine > RC Internal medicine > RC0254 Neoplasms. Tumors. Oncology (including Cancer) | ||||||||
| Divisions: | Faculty of Medicine > Warwick Medical School > Health Sciences > Clinical Trials Unit Faculty of Medicine > Warwick Medical School > Health Sciences Faculty of Medicine > Warwick Medical School |
||||||||
| Library of Congress Subject Headings (LCSH): | Thrombophlebitis -- Treatment, Cancer -- Complications | ||||||||
| Journal or Publication Title: | Journal of Clinical Oncology | ||||||||
| Publisher: | American Society of Clinical Oncology | ||||||||
| ISSN: | 0732-183X | ||||||||
| Official Date: | July 2018 | ||||||||
| Dates: |
|
||||||||
| Date of first compliant deposit: | 4 April 2018 | ||||||||
| Volume: | 36 | ||||||||
| Number: | 20 | ||||||||
| Page Range: | pp. 2017-2023 | ||||||||
| DOI: | 10.1200/JCO.2018.78.8034 | ||||||||
| Status: | Peer Reviewed | ||||||||
| Publication Status: | Published | ||||||||
| Access rights to Published version: | Restricted or Subscription Access | ||||||||
| RIOXX Funder/Project Grant: |
|
||||||||
| Related URLs: |
Request changes or add full text files to a record
Repository staff actions (login required)
 |
View Item |
